Hemogenyx Pharmaceuticals Plc Stock Book Value Per Share
| HOPHF Stock | USD 0 0.00 0.00% |
Hemogenyx Pharmaceuticals Plc fundamentals help investors to digest information that contributes to Hemogenyx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Hemogenyx Pink Sheet. The fundamental analysis module provides a way to measure Hemogenyx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hemogenyx Pharmaceuticals pink sheet.
Hemogenyx |
Hemogenyx Pharmaceuticals Plc Company Book Value Per Share Analysis
Hemogenyx Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Hemogenyx Pharmaceuticals Book Value Per Share | 0.01 X |
Most of Hemogenyx Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hemogenyx Pharmaceuticals Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Hemogenyx Pharmaceuticals Plc is about 0.007 times. This is 100.41% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The book value per share for all United States stocks is 100.0% higher than that of the company.
Hemogenyx Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hemogenyx Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hemogenyx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Hemogenyx Pharmaceuticals by comparing valuation metrics of similar companies.Hemogenyx Pharmaceuticals is currently under evaluation in book value per share category among its peers.
Hemogenyx Fundamentals
| Return On Equity | -0.32 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | 8.17 M | |||
| Shares Outstanding | 1.14 B | |||
| Shares Owned By Insiders | 13.01 % | |||
| Price To Book | 1.78 X | |||
| EBITDA | (2.39 M) | |||
| Net Income | (5.1 M) | |||
| Cash And Equivalents | 6.84 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 10.15 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 20.23 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (2.63 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 10 | |||
| Beta | 3.49 | |||
| Market Capitalization | 45.68 M | |||
| Total Asset | 8.52 M | |||
| Net Asset | 8.52 M |
About Hemogenyx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hemogenyx Pharmaceuticals Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hemogenyx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hemogenyx Pharmaceuticals Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Hemogenyx Pink Sheet
Hemogenyx Pharmaceuticals financial ratios help investors to determine whether Hemogenyx Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hemogenyx with respect to the benefits of owning Hemogenyx Pharmaceuticals security.